Bereskin & Parr LLP | Canada | 16 Oct 2018
Like other patents in Canada, drug patents have a term limited to twenty years from the filing date. However, unlike other products, drugs must…
Bereskin & Parr LLP | Canada | 29 Aug 2018
The vast majority of Canadian patents currently in force carry a term limited to twenty years from the filing date. However, as part of Canada’s…
Bereskin & Parr LLP | Australia, Canada | 20 Feb 2018
There were a number of important updates to the practice of intellectual property litigation in 2017. Most notably, the Patent Act and the Patented…
Bereskin & Parr LLP | Canada | 1 Nov 2017
On September 21 2017 changes to the Trademarks Act designed to increase and strengthen protection for geographical indications (GIs) as part of the…
Bereskin & Parr LLP | Canada, European Union | 20 Sep 2017
The Canadian government has chosen September 21 2017 as the date on which the majority of the act implementing the Comprehensive Economic and Trade…
Bereskin & Parr LLP | Canada | 11 Sep 2017
September 21, 2017 has been set by the Government of Canada as the date on which the majority of the Act implementing the Comprehensive Economic and…
Bereskin & Parr LLP | Canada | 23 Feb 2017
While a lot of attention has been placed over the last couple of years on major amendments to the Trade-marks Act, now scheduled to be implemented in…
Bereskin & Parr LLP | Canada, USA | 21 Feb 2017
This article summarizes Canadian developments in the past year relating to the protection of Life Science innovations. CETA signed - Patent term…
Bereskin & Parr LLP | Canada, European Union | 7 Nov 2016
On October 30, 2016, Canada and the European Union officially signed the Comprehensive Economic and Trade Agreement (CETA). Bill C-30, the CETA…
Bereskin & Parr LLP | Canada, European Union | 2 Nov 2016
Canada and Europe finally signed off on the Comprehensive Economic and Trade Agreement ("CETA"). Its most significant aspect for the pharma industry…